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Introduction: Gouty arthritis (gout) is primarily cared for in ambulatory care settings. Although the prevalence of
gout in the US is thought to be increasing, there have been few data on this as well as temporal changes in gout
medication use.
Methods: We analyzed annual visit and drug utilization data from national sample surveys of physician practices
and hospital outpatient clinics in the US from 1993 to 2009. Gout diagnosis was recorded by individual physicians.
Result: The frequency of visits for gout increased three-fold from 1993 through 2009; most of the increases were
observed from 2003 onwards. The increase was only partly explained by changes in age and gender composition
of the surveys over time. A concomitant increase in prescriptions for allopurinol and colchicine and decrease in
prescriptions for anti-inflammatories was observed. Aspirin use, a putative risk factor for gout and gout flares,
increased substantially over this period. Probenecid use was negligible. Frequency of systemic steroid use has not
changed over time.
Conclusions: The number of ambulatory visits for gout has increased almost three-fold in the first decade of the
millennium coinciding with increases in physician and patient awareness. This increase was primarily due to visits
among the elderly. Uricosuric use remained negligible whereas the uses of allopurinol and colchicine have
increased rapidly. Use of traditional non-steroidals has declined, possibly due to safety concerns whereas
glucocorticoid use remains unchanged.Introduction
Gout is a common type of arthritis that is mostly man-
aged in ambulatory (outpatient) care settings. Some re-
ports suggest that its prevalence may be increasing [1,2].
Over the past 20 years, therapies for gout have under-
gone some changes including the introduction and sub-
sequent withdrawal of Cox-1-sparing anti-inflammatory
therapies, increasing recognition of cardio-metabolic im-
pact of gout, and the poor health-related quality of life
associated with gout [3-8]. Cross-sectional studies and
short-term follow-up studies have suggested that uncon-
trolled gouty arthritis (gout) is associated with signifi-
cant health care utilization and costs in ambulatory care;
this is especially true among those with uncontrolled gout
[5,9,10]. However there have been few prospective studies* Correspondence: e.krishnan@stanford.edu
Department of Medicine, Stanford University, ARAMIS Program, Stanford, CA
94305, USA
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distribution, and reproduction in any mediumthat have addressed longer-term trends in ambulatory care
use and prescription of treatments for gout.
There were two goals for the present study. The first
was to assess the frequency of gout-related ambulatory
care visits in the US from 1993 through 2009. The sec-
ond was to describe the time trends in prescriptions for
urate-lowering treatment and anti-inflammatory therapy
for gout.
Methods
Data source and data description
This study used publicly available de-identified data, and
as per the Stanford institutional review board does not
constitute Human Subject Research, nor does it need in-
dividual participant consent.
Ambulatory care in the US is provided through two
distinct settings - hospital based clinics and non-hospital
based clinics. The latter includes freestanding privateentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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patient clinics. We used 17-year data from the National
Ambulatory Medical Care surveys (NAMCS) and National
Hospital Ambulatory Medical Care Surveys (NHAMCS)
from 1993 through 2009 to estimate the number of
medications. These two nationally representative, an-
nual, sister-surveys, conducted by the National Center
for Health Statistics collect demographic, diagnosis and
prescription data from a national sample of ambulatory
care visits to physician offices (NAMCS) and hospital-
based clinics (NHAMCS). Both NAMCS and NHAMCS
use multi-stage probability sampling design to obtain a
sample of visits that are representative of all outpatient
visits in the US for a given year. NAMCS data sampling
has three stages. In the first stage, primary sampling
units (PSUs) are selected from geographically defined
areas. In the second stage, a probability sample of prac-
ticing physicians is selected within each PSU. In the final
stage patient visits are selected within the annual practices
of sampling physicians. NHAMCS has similar sampling
design to NAMCS with the same first stage and the same
last stage, but it has two intermediate stages instead of
one. Hospitals within PSUs are sampled in the second
stage and then clinics within those hospital outpatient de-
partments are sampled further in the third stage. These
two care settings can be combined within years because
they have different sampling frames. The data elements
used in the present study have been collected without
changes over the study period from 1993 to 2009. So data
for 1993 to 2009 from the two surveys have the same
structure and hence they could be combined for the data
analysis. Extensive description of the survey and method-
ology are available in the public domain [11] (accessed 25
September 2012).
The NAMCS and NHAMCS data are mostly uni-
formly formatted for each year. For each record, besides
the design variables (PSU, Stratum and Weight) we have
the information as to whether or not the patient has
gout at that visit, and whether or not he/she takes gout-
related medications, such as colchicine, steroid, etcetera,
for gout.
Diagnoses
For each visit, up to three diagnoses directly related to
the visit, as determined by the physician, were coded
using International Classification of Diseases 9th revi-
sion, Clinical Modification codes. Thus, a visit exclu-
sively for sinusitis will be coded as having one diagnosis
(sinusitis) even if the patient had numerous other diag-
noses such as cancer, compression fractures, etcetera.
Prescription medications
Up to six medications either prescribed or continued
during the visit were coded and recorded using NationalDrug Code Directory (prior to 2006) and Lexicon Plus®
starting in 2006 [12] (accessed 20 September 2012).
Dosage information was not available. Anti-inflammatory
therapies were classified as followed: aspirin, non-aspirin
anti-inflammatories (including coxibs), systemic cortico-
steroids (prednisone, prednisolone, methyl prednisolone)
and colchicine.
Case definition of gout
In the NAMCS and NHAMCS datasets, a diagnosis
of gout can be inferred based on two data items, a
physician-assigned visit diagnosis, and a prescription
of gout medications. A number of patient visits were not
associated with recorded-visit diagnosis of gout but re-
ceived a prescription of allopurinol or colchicine (typically
refills), and vice versa. For the purpose of this study, a pa-
tient was determined to have gout if it was associated with
a recorded visit diagnosis of ICD-9 CM code 274.*, and/or
had a prescription of allopurinol or colchicine. Additional
clinical information about gout severity and chronicity
were not available.
Inclusion and exclusion
We excluded all patients with age <20 or >90 years for
analyses that involved gout, because gout is very rare in
the younger category, and the number of observations in
the >90 years category were too few.
Statistical analyses and interpretation
Data characteristics
There are two special aspects of NAMCS and NHAMCS
datasets that have a bearing on the statistical analyses.
The first is the complex survey design that mandated
incorporation of design factors and survey weights, for
overall analyses and analyses within the subsets (domains).
This was accomplished using SVY module of the soft-
ware STATA 12.1® (Statacorp College Station, TX, USA).
NAMCS and NHAMCS are surveys intended to obtain
a snapshot of ambulatory care utilization and not popula-
tion prevalence of disease, such as the NHANES (National
Health and Nutrition Examination Survey). The second
unique aspect about these data is that the sampling
was intended to obtain a sample of visits and not pa-
tients. While this sample may be similar to the sam-
ple of all patients in the ambulatory clinics, it is not
necessarily designed to be so. Patients with gout, who
happen to visit the clinic more than once in the en-
rollment period, will be counted as two independent
visits. Conditions with higher health-care utilization
are likely to be represented disproportionate to their
true prevalence in the population, whereas those of
low utilization and short natural history will be
under-represented. The estimates of the number of
visits and prescriptions were considered reliable only
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estimate/estimate) was ≤30%.
Proportions, counts and rates
For the present analyses we calculated proportions and
rates to assess the relative magnitudes. The numerators
and denominators of the estimated proportions pre-
sented here are the numbers of visits unless specified
otherwise. The estimated count of the visits for gout and
the count of the number of prescriptions of medications
were calculated by applying survey weights. Counts were
rounded off to their nearest thousands or millions as
appropriate.
Trend analyses
The bivariate changes in counts, proportions and rates
over time were assessed visually as well formally. Trend
curves were graphically fitted using polynomial regres-
sion, as they provided better fits to the non-linear data.
Calendar year was treated as a continuous measure for
trend testing. Wherever relevant the years were col-
lapsed to 4- to 5-year categories.
The impact of changes in age and gender profile on
the observed trends was accounted for by log-binomial
implementation of generalized linear models (propor-
tions), specifying survey weights and sampling units. The
magnitude of trends was summarized by relative risk esti-
mates/odds ratios.
Results
Description of the dataset
The dataset, prior to any exclusions, included 1.01 million
ambulatory-care visit records from 1993 to 2009. We ex-
cluded 233,000 visits for patients age <20 years and 4,734
visits for patients age > 90 years, leaving 782,000 visits
eligible for inclusion by age criterion. Of these, 4,683
patients/visits met the case definition of gout. Within
the 4,683 visits in the gout group, there were 3,119 visits
where allopurinol was prescribed and 54 with probenecid
prescriptions. There were 854 prescriptions of non-
aspirin, non-coxib anti-inflammatories, 732 prescriptions
for aspirin, 115 prescriptions for coxib, and 839 prescrip-
tions for colchicine.
Estimated ambulatory visits for gout in the year 2009
In the year 2009 there were 12.1 (95% confidence inter-
val (9.0, 15.2)) million ambulatory care visits for gout
out of a nationwide estimated 900 (750, 1100) million
visits in the 20- to 90-years age category. Of these 8.9
(6.6, 11.2) million were men and 3.2 million (2.2, 4.3)
were women. There were 8.7 million (6.3, 11.2) prescrip-
tions for allopurinol, 2.3 million (1.4, 3.1) prescriptions for
colchicine, 1.7 (1.0, 2.4) million prescriptions for non-
aspirin non-coxib non-steroidal anti-inflammatory drugs(NSAIDS), 409,000 (80,000, 736,000) prescriptions for
coxibs 2.7 (1.8, 3.6) million prescriptions for aspirin, and
488,000 (182,000, 794,000) prescriptions for steroids.
Time trends
Overall number of ambulatory visits and visits for specific
causes
From 1993 to 2009 in the US, the estimated number
of ambulatory care visits (for any reason) in the age cat-
egory 20 to 90 years increased from 600 (520, 680) million
to 900 (750, 1100) million visits. Overall, the prevalence of
visits for gout, as a proportion of all visits recorded in-
creased with age among men and women (Figure 1). Visits
for musculoskeletal diagnoses (ICD9-CM 710.*-739.*) in
general showed an increasing trend but the trend pre-
ceded the rise of visits for gout and appears to be a part a
secular trend (Figure 2). When visits for rheumatoid arth-
ritis (ICD9-CM 714.*) were examined, no time trends
were observed.
Age and gender
Over the period of observation the mean age of patients
seeking outpatient care in the US increased from 51 years
(51, 52) to 55 years (54, 55). Among those who met our
case definition of gout, the mean age was essentially un-
changed: 65 (61, 69) versus 65 (64, 67). Overall, the pro-
portion of men in the dataset was unchanged over time
at approximately 38%. Among those with gout the pro-
portion of men in 1993 was 71% (58%, 81%) and in 2009
was 73% (68%, 79%).
Gout
The estimated number of visits with gout in 1993 was
4.1 (2.9, 5.3) million and this rose to 12.1 (9.0, 15.2) mil-
lion in 2009 (P <0.001). This increase was observed in men
and women (Figures 2 and 3). When examined by age, the
increases were statistically significant for age >60 years
among men, and among women in the 60- to 79-year
age category (Table 1). Gout as a proportion of all visits
decreased between 1993 and 2000 among women but
subsequently showed an increase in both men and
women (Figure 4). Compared to 1993, there were no sta-
tistically significant increases in the proportion among
women but the proportion increased among men from
13 per 1,000 (10, 17) in 1993 to 26 per 1,000 (21, 31)
in 2009. The trends were unchanged when data were
reanalyzed after redefining gout exclusively based on
the ICD code.
In bivariate logistic regressions models each advancing
year was associated with an odds ratio of 1.05 (1.03, 1.06).
In multivariable logistic regression models that included
age, sex and year, the corresponding odds ratio was 1.04
(1.03, 1.06). When the year variable was categorized as in
Table 1, the period 2006 to 2009 was associated with an
Figure 1 Age-sex distribution of gout in ambulatory care settings in the US, National Ambulatory Health Care surveys, 1993 to 2009.
Prevalence was calculated as a proportion of all the ambulatory care visits in hospital-based clinics as well as physician offices in the US.





































































Figure 2 Time trends in gout visits contrasted with those for all musculoskeletal diagnoses (ICD9-CM 710.* to 739.*) and with those
for rheumatoid arthritis (ICD9-CM 714.*). RA, rheumatoid arthritis; MSK, musculoskeletal diagnoses.








































Figure 3 Time trends in the estimated number of ambulatory care visits for gout in the US: data from the National Ambulatory Health
Care Surveys 1993 to 2009.
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odds ratio of 1.6 (1.4, 1.9) in age- and sex-adjusted logistic
regressions.
Medications prescribed
Figure 5 shows the proportion of visits for gout where
each medication was prescribed among those who met
the case definition for gout. The trends for colchicine
and steroids were not statistically significant. In logistic
regressions that were adjusted for age and sex, each ad-
vancing year was associated with a significant increase in
the use of allopurinol with an odds ratio of 1.02 (1.00,
1.05; P = 0.048) and the use of aspirin with an odds ratio
of 1.09 (1.05, 1.12). The use of non-coxib NSAIDs de-
creased with a yearly odds ratio of 0.96 (0.94, 0.99).
There were no significant trends in other medications.
Combination treatment in gout
The estimate of visits with concurrent prescriptions of
allopurinol and probenecid was negligible, with approxi-
mately 50,000 over the observation period. These esti-













20 to 39 704,285 1,039,594 769,990 1,591,411 0.09
40 to 59 3,658,756 4,903,678 5,746,758 7,944,502 0.07
60 to 79 5,590,948 5,836,312 10,280,899 14,921,770 <0.00
> = 80 800,007 1,585,809 2,617,818 3,721,661 0.006
Overall 10,753,996 13,365,393 19,415,465 28,179,344
aP-values are for trend: the test was performed using bivariate logistic regression mthus, unreliable (relative standard errors >30%). The pro-
benecid data were not analyzed further.
Overall, the combination of colchicine and any one of
the NSAIDS were prescribed in 3.5 million (2.4 to 4.6
million) gout patients, representing 3.6% (2.6%, 4.8%) of
all gout visits. The confidence intervals of these esti-
mates were conservative as they overlap, whereas the P-
value for the difference in proportion was statistically
significant at 0.01. On further evaluation this was deter-
mined to be due to the conservativeness (biasing to-
wards the null) of the standard error estimate compared
to hypothesis testing and P-values [13].
The proportion of such combinations increased from
2.02 (1.2, 3.3) in the 1993 to 2000 period, to 4.3 (3.1, 6.1)
in the 2001 to 2009 period. In unadjusted logistic regres-
sion this change represented an odds ratio of 2.4 (1.3, 4.5)
and in age- and sex-adjusted logistic regression the odds
ratio was unchanged. Combinations of NSAIDS and ste-
roids were rare, and were prescribed in 1.7% of gout visits
(1.1%, 2.8%). These proportions were similar in the 1993
to 2000 and 2001 to 2009 periods: 1.3% (0.6%, 2.8%) and











136,926 199,082 105,708 280,295 0.62
1,180,143 965,395 2,037,772 1,409,484 0.81
1 2,192,226 2,456,175 3,604,061 5,349,247 0.01
1,172,668 851,594 1,784,431 3,005,855 0.06
4,681,963 4,472,246 7,531,972 10,044,881





































Figure 4 Trends for gout as a proportion of all ambulatory visits in the US: data from the National Ambulatory Health Care Surveys
1993 to 2009. Trend lines and 95% confidence bands were fitted using fractional polynomial regression. Gout was defined as a physician
diagnosis of gout or prescription of allopurinol/colchicine.
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The number of ambulatory care visits for gout has in-
creased substantially over time. Increase in age and
changes in gender distribution in the survey participants
explained some, but not all of the increases in the
prevalence of gout. The large magnitude of this increase
also cannot be explained by the modest changes in popu-
lation incidence and prevalence of gout [2,14,15]. The60
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Figure 5 Time trends in medications prescribed for gout in the US: d
2009. Trend lines and 95% confidence bands were fitted using fractional p
gout or prescription of allopurinol/colchicine. NSAID, non-steroidal anti-inflNAMCS and NHAMCS data collection strategies have
not changed substantially either. We propose that this
phenomenon may be causally linked to the extensive pa-
tient and physician gout awareness programs led by man-
ufacturers of urate-lowering therapies and entities such as
the Gout and Uric acid Society since 2005. The date of 22
May was designated as the Gout Awareness Day. Effective
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ata from the National Ambulatory Health Care Surveys 1993 to
olynomial regression. Gout was defined as a physician diagnosis of
ammatory drugs.
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in rotation on the News section of the USAToday website
[16]. The advertisement attracted more than 1% click-
through rate on the news feed and readers spent more
than 2 minutes and 30 seconds with the content. In just
two weeks and over 2 million clicks, more than 20,000
USA Today readers spent time learning about gout. The
media attention to vice president Dick Cheney’s gout may
have a role as well, just as the first lady, Betty Ford’s breast
cancer diagnosis that was credited with a transient in-
crease of breast cancer incidence in the mid 1970s [17].
Lastly, the number of publications on gout also showed
a significant increase over time, in part due to the fund-
ing from manufacturers and in part from the interest gen-
erated from the arrival of new products to treat gout
(Figure 6). While these possibilities might be interesting,
they are not testable hypotheses in our datasets.
We considered other possible explanations for a steep
increase such as the epidemic of obesity, increasing
utilization of low-dose aspirin, and the higher utilization
of high-fructose corn syrup or such dietary changes, but
rejected them as the rate of increase was so obviously
disproportionate to such long-term trends.
To our knowledge, this is the first nationally represen-
tative study that reports time trends in the use of gout
medications in the US population. Table 2 summarizes
all the recent studies that have addressed the epidemi-
ology of gout and gout medications in the ambulatory
care settings. The designs, scope of enrollment and study
duration are too heterogeneous to permit head to head
comparison with our study. The proportion of patients/
visits with allopurinol prescriptions varies widely de-
pending on the case definition used to identify gout. The
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Figure 6 Time trends in the number of publications in PubMed that m
Data source: Alexandru-Dan Corlan. Medline trend: automated yearly statist
http://dan.corlan.net/medline-trend.html. Accessed 14 February 2012, Archicomparable to the average proportion observed in the
present study.
The trends that we have documented in urate-
lowering medication are similar to those observed in the
UK ambulatory-care settings with stable use of all medi-
cations except anti-inflammatory drugs, which showed a
significant decline [18]. Ever since the introduction of
allopurinol as a therapy by Gertrude Elion, allopurinol
had held sway as the mainstay of urate-lowering therapy
for gout [15,19]. Nevertheless, allopurinol has been under-
prescribed and under-dosed, resulting in poor urate con-
trol and consequently worse health outcomes and higher
costs of care [5,10,20-27]. Unlike the UK data where the
proportion of patients with urate-lowering therapies was
between 25% and 30%, the proportion of prescriptions for
allopurinol in our study was much higher.
Recently, uricosuric therapy has generated much inter-
est on account of availability of newer agents [28-30].
Probenecid, an old uricosuric agent, gained popularity
transiently in the past, but has fallen out of favor due to
the dosing schedule, concerns about urolithiasis and re-
duced efficacy in the presence of azotemia [29]. In the
present study probenecid prescriptions were observed to
increase over time, but these increases were too few to
reach statistical significance.
The combination of xanthine oxidase inhibitors and
uricosuric agents as a means to achieve better urate effi-
cacy did not gain popularity in light of earlier pharmacoki-
netic studies suggesting that probenecid increases renal
clearance of oxypurinol, the active metabolite of allopur-
inol [31]. The number of prescriptions for combination
therapy of probenecid and allopurinol was negligible,
although there are no explicit adverse effects associated
with combination therapy, even though more recent clinicalYear
980 1985 1990 1995 2000 2005 2010
entioned gout in the title, abstract or Medical Subject Headings.
ics of PubMed results for any query, 2004. Web resource at URL:
ved by WebCite at http://www.webcitation.org/65RkD48SV.














Case definition of gout Number of gout
cases/visits/episodes
Proportion of patients (%)a
Allopurinol Colchicine Any NSAID Systemic steroids
Primatesta (2011), US 1 No Yes 1996 to 2008 ICD codes and gout medication
prescription
177,637 36 18 43 20
Reidel (2010), US 1 No Yes 1997 to 1998 ICD codes and gout medication
prescription
9,595 66 15 NA NA
Roddy (2010), UK 2 No No 2001 to 2004 Proprietary diagnosis odes 673 23 15 73 0
Annemans (2008), UK 2 No No 2000 to 2005 ICD codes and/or medical record text
mentions of gout, and prescription
34,071 89 16 89 26
Annemans (2008), UK 2 No No 2000 to 2005 ICD codes and/or medical record text
mentions of gout, and prescription
34,797 93 15 80 14
Harris (1995), UK 3 No No 1993 General practitioner diagnosis 2,865 46 NA NA NA
Mikuls (2005), UK 2 No No 1990 to 1999 Proprietary diagnosis codes 63,105 25 to 30 1 to 3 40 to 66 5%
Cea Soriano (2011), UK 2 No No 2000 to 2007 Proprietary diagnosis codes 24,768 28 14 19 NA
Krishnan (2005), US 4 No Yes 2002 ICD codes and prescriptions 206a 69 4.6 18 6.9
Present study, USc 4 Yes Yes 1993 to 2009 ICD codes alone 100.4 million (1,634b) 35 15 34 10
Present study, USc 4 Yes Yes 1993 to 2009 ICD codes and/or prescriptions 35.9 million (4,781b) 69 17 23 6.8
Settings type 1) Medical and pharmacy insurance claims; 2) General Practice case records with linked pharmacy records; 3) Survey of General practitioners; 4) Nationally representative sample survey of all ambulatory
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drugs may be additive [32]. With increasing acceptance of
the treat-to-target approach, we would expect a greater role
for the combination therapy with xanthine oxidase inhibi-
tors and uricosuric agents.
Gout in the general practice settings is often an epi-
sodic disease; the treatment is also often ad hoc, using col-
chicine and anti-inflammatory drugs. Anti-inflammatory
drugs, often recommended as a first line of therapy, have
been falling out of favor due to the recognized adverse
effects such as gastrointestinal bleeds, renal failure
and hypertension [33,34]. The overall utilization of
anti-inflammatory drugs has decreased in the US. Col-
chicine, an ancient remedy for acute gout flares, has been
utilized more frequently. It is unlikely that any of the colchi-
cine prescriptions recorded during the latest year of the
study, 2009, was for the proprietary formulation. Systemic
steroids offer inflammation control for acute gout flares and
may be preferable for those with renal disease and other
contraindications for colchicine and anti-inflammatory
drugs. The utilization of these did not change over time.
The estimates presented here need to be considered in
the context of the characteristics of the data collection
strategies. First, these data do not include those from
federal hospitals such as the Veterans Affairs-owned
hospitals. Many such hospitals are known to have a high
prevalence of gout. The uninsured patients are likely to
be under-represented in ambulatory-care data. Thus, our
estimates are likely to be lower than the true number of
visits. Second, although the diagnosis of gout was made
by the physician, it was not standardized, leaving room
for misclassification errors. Third, the denominator of
our estimated proportions is the total number of visits,
not total number of patients or total number of preva-
lent cases of gout. Fourth, not prescribing a specific
medication during a visit does not necessarily represent
a lack of knowledge, interest or intent on the part of
the physician; it may reflect individual clinical realities
(for example, contraindications, competing hazards from
therapeutic alternatives) and patient preference [35-37].
Such granularity of data, which is needed to determine the
appropriateness of prescription, is not collected in the
Ambulatory care surveys.
Comparisons of the estimates in the present study
with those from contemporaneous population surveys
are not easy but are tempting. The NHANES 2009 to
2010 surveys estimated that there were about 8 million
cases of gout prevalent in the US, whereas the present
study estimated 12 million outpatient visits in 2009.
However, the proportion of gout as a cause of all-cause
ambulatory visits in the present study is smaller at 0.80%
(0.75%, 0.85%) than the prevalence rate of gout esti-
mated in the NHANES 2009 to 2010 (3.8%). These two
comparisons suggest that the health care utilization ratesfor gout may be lower than what might be expected
from the population prevalence of gout. The disparities
have other potential explanations as well: in the present
study, the data on diagnoses were restricted to active
problems, with the premise that no more than three
problems are likely to be addressed in a single ambulatory
care visit. Thus inactive problems, such as remote history
of gout, are unlikely to be recorded. In the NHANES,
there was a dedicated question about physician/provider-
diagnosed gout. The implication is that the estimates of
gout from the present study may reflect the point preva-
lence as opposed to lifetime prevalence assessed by the
NHANES. Second, the mode of diagnosis in the present
study was physician diagnosis and physician-prescribed
medications, whereas in NHANES it was health-care pro-
vider diagnosed gout. Some of the disparities may reflect
higher diagnostic errors in the NHANES data than the
present data.
Conclusions
In conclusion, we have documented the ambulatory care
utilization of gout and gout medications in the 1990s and
the first decade of the millennium. These data would serve
as a baseline for future pharmaco-epidemiologic studies
that will include the newer therapies and help identify
areas in health care delivery where quality of care can be
optimized and outcomes improved.
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